bendamustine + rituximab + pixantrone

This is a combination regimen of three drugs—bendamustine, rituximab, and pixantrone—investigated primarily for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Bendamustine is a chemotherapeutic agent with both alkylating and antimetabolite properties that induces cell death through apoptotic and nonapoptotic pathways. Rituximab is a monoclonal antibody targeting CD20 on B lymphocytes, leading to their destruction via immune-mediated mechanisms. Pixantrone is an aza-anthracenedione chemotherapeutic designed to reduce cardiotoxicity compared to similar agents; it intercalates into DNA and inhibits topoisomerase II, causing DNA damage and cell death. The combination aims to leverage complementary mechanisms for improved efficacy in aggressive or relapsed/refractory lymphomas[1][4][7][8].

Other names

BuRP (for the combination)PREBEN (when used with etoposide, but not in this specific combination)